Vantage 2020 Preview

Vantage 2020 Preview Highlights


  • The US political scene and issues around drug pricing are driving investor uncertainty
  • There are few signs that the US FDA’s industry-friendly stance will substantially shift next year
  • Abbvie’s Humira is expected to be 2020’s biggest seller, but Merck & Co’s Keytruda has the strongest forecast growth
  • Trastuzumab deruxtecan (Daiichi Sankyo / AstraZeneca) is 2020’s most lucrative potential approval, with forecast sales of over $2bn in 2024
  • AstraZeneca will be the fastest growing drug company in 2020, projected to add over $3bn in new sales

Download Your Copy

Lorem ipsum dolor

Aenean commodo ligula eget dolor.

  • Lorem ipsum dolor sit amet, consectetuer adipiscing elit.
  • Aenean commodo ligula eget dolor.
  • Aenean massa consequat massa quis enim. nenatis vitae, justo

Lorem ipsum dolor sit amet

Lorem ipsum dolor

Aenean commodo ligula eget dolor.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.

Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.

Lorem ipsum dolor

Aenean commodo ligula eget dolor.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.

Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.

Lorem ipsum dolor

Aenean commodo ligula eget dolor.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.

Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.

Click Here

Pricing and politics set up volatile year ahead


The industry closed 2019 with a flourish, and areas like cancer, vaccines and diabetes are poised to continue this with strong sales in 2020.

However, the wider sector will need to deliver on its innovation promises next year if it hopes to rise above wider economic and financial concerns.

Lorem ipsum dolor

Aenean commodo ligula eget dolor.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.

Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.

Lorem ipsum dolor

Aenean commodo ligula eget dolor.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.

Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.

Download Report

EvaluateVantage 2020 Preview

Aenean commodo ligula eget dolor.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.

Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.

Click Here

Lorem ipsum dolor

Aenean commodo ligula eget dolor.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.

Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.

Click Here
Click Here

Mauris Interdum Vehicula

Lorem ipsum dolor sit amet, consectetuer adipiscing elit.

Read More

Mauris Interdum Vehicula

Lorem ipsum dolor sit amet, consectetuer adipiscing elit.

Read More

Lorem ipsum

Download our white papers

Three resources for the professionally curious

Schedule EvaluatePharma Vision demo >
Stimulus      
Daily news with expert analysis
Interviews with industry leaders
Company & product events coverage
Response      
Consensus forecasts to 2024  
Archived consensus forecasts  
Sales by indication  
Therapy area, mechanism of action, and other classifications  
Licensing deals, M&A, venture financing and IPOs  
Orphan drugs and biosimilars analysis  
Success rate benchmarks (PTRS)    
Time-in-phase benchmarks by indication    
Comprehensive product and trial level R&D costs    
Clinical trials design and outcomes    
Net Present Value calculator    
Calendar of market events and catalysts    

TESTIMONIAL